Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

DUSP5P1 promotes gastric cancer metastasis and platinum drug resistance [ChIRP-seq]

ABSTRACT: DUSP5P1 promotes gastric cancer metastasis and platinum drug resistance [ChIRP-seq]

PROVIDER: PRJNA881456 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR21614748_1.fastq.gz	Fastqsanger.gz
	SRR21614748_2.fastq.gz	Fastqsanger.gz
	SRR21614749_1.fastq.gz	Fastqsanger.gz
	SRR21614749_2.fastq.gz	Fastqsanger.gz
	SRR21614750_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 6

Similar Datasets

DUSP5P1 promotes gastric cancer metastasis and platinum drug resistance [ChIRP-seq]

Project description:We elucidated the functional significance and molecular mechanisms of DUSP5P1 lncRNA (dual specificity phosphatase 5 pseudogene 1) in gastric carcinogenesis. We demonstrated that gastric cancer (GC) patients with high DUSP5P1 expression had shortened survival in two independent cohorts. DUSP5P1 promoted GC cell migration and invasion in vitro and metastasis in vivo. Mechanistically, DUSP5P1 activated ARHGAP5 transcription by directly binding to the promoter of ARHGAP5 with a binding motif of TATGTG. RNA-seq revealed that ARHGAP5 activated focal adhesion and MAPK signalling pathways to promote GC metastasis. DUSP5P1 also dysregulated platinum drug resistance pathway. Consistently, DUSP5P1 overexpression in GC cells antagonized cytotoxic effect of Oxaliplatin, and shDUSP5P1 plus Oxaliplatin exerted synergistic effect on inhibiting GC metastasis in vitro and in vivo. DUSP5P1 depletion also suppressed the growth of platinum drug-resistant PDO models. In conclusion, DUSP5P1 promoted GC metastasis by directly modulating ARHGAP5 expression to activate focal adhesion and MAPK pathways, serves as therapeutic target for platinum drug resistant GC, and is an independent prognostic factor in GC.

2022-11-18 | GSE213581 | GEO

DUSP5P1 promotes gastric cancer metastasis and platinum drug resistance [RNA-seq]

2022-11-18 | GSE213560 | GEO

DUSP5P1 promotes gastric cancer metastasis and platinum drug resistance

Project description:DUSP5P1 promotes gastric cancer metastasis and platinum drug resistance

| PRJNA881448 | ENA

DUSP5P1 promotes gastric cancer metastasis and platinum drug resistance [RNA-seq]

Project description:DUSP5P1 promotes gastric cancer metastasis and platinum drug resistance [RNA-seq]

| PRJNA881345 | ENA

DUSP5P1 promotes gastric cancer metastasis and platinum drug resistance

Project description:This SuperSeries is composed of the SubSeries listed below.

2022-11-18 | GSE213582 | GEO

DUSP5P1 promotes gastric cancer metastasis and platinum drug resistance.

Project description:We elucidated the functional significance and molecular mechanisms of DUSP5P1 lncRNA (dual specificity phosphatase 5 pseudogene 1) in gastric carcinogenesis. We demonstrated that gastric cancer (GC) patients with high DUSP5P1 expression had shortened survival in two independent cohorts. DUSP5P1 promoted GC cell migration and invasion in vitro and metastasis in vivo. Mechanistically, DUSP5P1 activated ARHGAP5 transcription by directly binding to the promoter of ARHGAP5 with a binding motif of TATGTG. RNA-seq revealed that ARHGAP5 activated focal adhesion and MAPK signaling pathways to promote GC metastasis. DUSP5P1 also dysregulated platinum drug resistance pathway. Consistently, DUSP5P1 overexpression in GC cells antagonized cytotoxic effect of Oxaliplatin, and shDUSP5P1 plus Oxaliplatin exerted synergistic effect on inhibiting GC metastasis in vitro and in vivo. DUSP5P1 depletion also suppressed the growth of platinum drug-resistant PDO models. In conclusion, DUSP5P1 promoted GC metastasis by directly modulating ARHGAP5 expression to activate focal adhesion and MAPK pathways, serves as therapeutic target for platinum drug resistant GC, and is an independent prognostic factor in GC.

| S-EPMC9616843 | biostudies-literature

RNA-Seq of treatment response of platinum sensitive and platinum resistant ovarian cancer cells

Project description:Resistance to platinum-based chemotherapy is a clinical challenge in the treatment of ovarian cancer (OC) and limits survival. Therefore, innovative drugs against platinum-resistance are urgently needed. Our therapeutic concept is based on the conjugation of two chemotherapeutic compounds to a monotherapeutic pro-drug, which is taken up by cancer cells and cleaved into active cytostatic metabolites. Here, we explore the activity of the duplex-prodrug 5-FdU-ECyd, covalently linking 2'-deoxy-5-fluorouridine (5-FdU) and 3'-C-ethynylcytidine (ECyd), on platinum-resistant OC cells. RNA-Sequencing was used for characterization of 5-FdU-ECyd treated platinum-sensitive A2780 and isogenic platinum-resistant A2780cis.

2018-02-22 | GSE98230 | GEO

Gastric Cancer Genetic Analysis of Metastasis

Project description:<p>To identify candidate drivers involved in oncogenesis and tumor evolution, we conducted an extensive genome sequencing analysis of metastatic progression in diffuse gastric cancer. This involved a comparison between a primary tumor from a Hereditary Diffuse Gastric Cancer Syndrome proband and its subsequent recurrence as an ovarian metastasis.</p>

| phs000795 | dbGaP

Competitive RNA Pair Controls Gastric Cancer Metastasis

Project description:Competitive RNA Pair Controls Gastric Cancer Metastasis

| PRJNA418152 | ENA

RNA sequencing of human gastric cancer drug treatment organoids

Project description:Using RNA sequencing, we profile transcriptome dervied from human gastric cancer organoids after drug treatment.

2023-03-02 | GSE220137 | GEO